Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Sedatives in neurocritical care

an update on pharmacological agents and modes of sedation

Opdenakker, Oliviera; Vanstraelen, Annaa,b; De Sloovere, Veerleb; Meyfroidt, Geerta,c

Current Opinion in Critical Care: April 2019 - Volume 25 - Issue 2 - p 97–104
doi: 10.1097/MCC.0000000000000592
NEUROSCIENCE: Edited by Mauro Oddo
Buy
SDC

Purpose of review In this article, the specific and general indications for sedatives in the neurocritical care unit are discussed, together with an overview on current insights in sedative protocols for these patients. In addition, physiological effects of sedative agents on the central nervous system are reviewed.

Recent findings In the general ICU population, a large body of evidence supports light protocolized sedation over indiscriminate deep sedation. Unfortunately, in patients with severe acute brain injury, the evidence from randomized controlled trials is scarce to nonexistent, and practice is supported by expert opinion, physiological studies and observational or small interventional trials. The different sedatives each have different beneficial effects and side-effects.

Summary Extrapolating the findings from studies in the general ICU population suggests to reserve deep continuous sedation in the neuro-ICU for specific indications. Although an improved understanding of cerebral physiological changes in patients with brain injury may be helpful to guide individualized sedation, we still lack the evidence base to make broad recommendations for specific patient groups.

aDepartment of Intensive Care Medicine, University Hospitals Leuven

bDepartment of Anesthesiology, University Hospitals Leuven

cLaboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

Correspondence to Geert Meyfroidt, Department and Laboratory of Intensive Care Medicine, University Hospitals and University of Leuven, Herestraat 49, 3000 Leuven, Belgium. Tel: +3216 344021; e-mail: geert.meyfroidt@uzleuven.be

Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.